Diagnostic Role Of Resistin In Nonalcoholic Fatty Liver Disease

Amal Shawky Mohamed, Engy Yousry Elsayed, Hala Abd Elal* and Iman H. Hewedi**
Internal Medicine, Clinical Pathology* and Pathology** Departments
Faculty Of Medicine, Ain Shams University, Cairo, Egypt.
amalshawky-mb@hotmail.com, ashorengy@yahoo.com, hala_abdelal@yahoo.com, imihewedi99@yahoo.com

Abstract: Introduction: Nonalcoholic fatty liver disease (NAFLD) is a major cause of liver-related morbidity and mortality. Insulin resistance is believed to be a key factor in the development of fatty liver. Moreover, insulin resistance states characterized by elevated expression and production of several cytokines; of particular adiponectin, leptin, resistin. Leptin and adiponectin have been implicated in the pathogenesis and progression of NAFLD but direct evidence of the role of resistin in NAFLD is lacking. The aim of this study was to determine the circulating resistin level in patients affected by NAFLD and to correlate resistin level with insulin sensitivity, liver function and histological features. Subjects and methods: This study included 100 subjects divided into: Forty patients with NAFLD, forty obese persons with BMI >30 having normal transaminases and normal liver ultrasound, and twenty controls with BMI < 20. For all subjects serum resistin was measured, Homeostasis model assessment (HOMA) was calculated and liver profile was assessed. Liver biopsy was done in NAFLD patients. Results: Serum resistin was higher in patients with NAFLD (16.2 ± 4) compared to obese and control groups (6.8 ± 4.1 and 3.4 ± 1.1) respectively (p <0.01). Serum resistin was higher in histologically advanced cases of NAFLD compared to simple steatosis (19.2± 3.6 vs. 13.5±2.7) respectively (p < 0.01). Moreover serum resistin was positively correlated to BMI, HOMA, highly sensitive CRP, AST and ALT. Conclusion and recommendation: Resistin has a role in pathogenesis of NAFLD, resistin level is a predictive of histology in NAFLD, so the use of serum resistin assay as a simple diagnostic biomarker for NAFLD is recommended.


Key word: NAFLD, NASH, Obesity and Resistin.

Introduction:
Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized as a potential serious condition, which can progress to cirrhosis, liver failure and hepatocellular carcinoma and has a worldwide distribution. The biological basis of variability in histological progression of NAFLD is unknown, consequently, it has become extremely important to understand the patho-physiology of NAFLD to develop sound therapeutic interventions. It is now recognized that non hepatic mechanisms are largely responsible for the development of insulin resistance, which causes hepatic steatosis. Insulin resistance is believed to be a key factor in the development of fatty liver. Moreover, insulin resistance states characterized by elevated expression and production of several cytokines; of particular adiponectin, leptin, resistin. Leptin and adiponectin have been implicated in the pathogenesis and progression of NAFLD. Resistin is a recently discovered signal molecule, which could help elucidation of the patho-physiology of the insulin resistance and its correlation with obesity. Leptin and adiponectin have been implicated in the pathogenesis and progression of non-alcoholic steatohepatitis (NASH) and chronic hepatitis C (CHC), but little is known about the role of resistin in chronic liver diseases.

The Aim of this work was to determine the circulating resistin level in patients affected by NAFLD and to correlate resistin level with insulin sensitivity, liver function and histologic features.

Subjects and methods: 100 subjects recruited from the hepatology clinic of Ain Shams University Hospital were enrolled in this study, they were divided into:
Group 1: Forty patients with NAFLD, diagnosis was based on chronic elevation of transaminases (>1.5 times the upper normal value for 3 months or longer), absence of hepatitis B and C virus markers, absence of autoantibodies indicative of autoimmune hepatitis, absent alcohol consumption and bright liver at ultrasound scanning, with body mass index (20-35 kg/m²).
Group 2: Forty obese persons with body mass index above 30 kg/m² having normal transaminase values and normal liver ultrasound.
Group 3: Twenty age and sex matched healthy subjects with body mass index 20-25 kg/m².

None of patients and control subjects was taking lipid-lowering medications, met-formin or thiazolidinediones. Written informed consent was obtained from all participants.

For all subjects the following was done: 1. Full history taking. 2. Clinical examination with evaluation of body mass index (BMI) which is equal to weight in kg /height in m².
3: Laboratory examination: CBC, ESR, fasting and 2 h pp blood glucose, fasting insulin, renal function [Sr, BUN, Na, K], liver profile [ALT, AST, GGT, ALP, bilirubin (total, direct), albumin, total protein, PT, INR], lipid profile [total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), cholesterol, triglycerides], high-sensitivity C-reactive protein (Hs CRP), HCV Ab, HBs Ag, HBV C Ab, ANA, AMA, ASMA, LKM, and ferretin.

4: The level of serum resistin was measured by ELISA method.

5: Insulin resistance was estimated by homeostasis model assessment (HOMA) = Fasting insulin X Fasting glucose / 22.5.

6. Abdominal Ultrasonography using real time scanning device Toshiba, vision 200 (SSA, 320A) with convex probe 3.5-5 uHz, focusing on liver size, texture, visualization of intra-hepatic vessels and diaphragm, liver to kidney contrast ratio.

7: Histological Analysis was done only for NAFLD patients (Group 1). Ultrasound guided liver biopsies were obtained using a 16-gauge Klatskin needle. A liver specimen of 15 mm with at least 10 portal tracts was considered adequate for evaluation. Only hematoxylin and eosin (H&E) stain was necessary to perform this study evaluation. Biopsies are blindly evaluated according to the published, validated semiquantitative feature-based scoring system proposed by Kleiner et al to calculate the NAFLD Activity Score (NAS). NAS specifically includes only features of active injury that are potentially reversible in the short term. The score is defined as the sum of the scores for steatosis (0-3), lobular inflammation (0-3), and ballooning injury (0-2); thus ranging from 0 to 8 (Figure 1). The system of evaluation is as follows: Steatosis (low- to medium power evaluation of parenchymal involvement by steatosis): 0; <5%, +1; 5%-33%, +2; >33%-66%, +3; >66%. Lobular inflammation (overall assessment of all inflammatory foci): 0; no foci, +1; < 2 foci per 200× field, +2; 2-4 foci per 200× field, +3; > 4 foci per 200× field. Ballooning injury: 0; none, +1; few balloon cells, +2; many cells/prominent ballooning. Fibrosis, which is both less reversible and generally thought to be a result of disease activity, is not included as a component of the activity score. A diagnostic categorization of Group 1 was formulated based on NAS: biopsies with scores of less than 3 were diagnosed as “not NASH” (Group 1a), NAS of ≥ 5 correlated with a diagnosis of “NASH” (Group 1c), while cases with activity scores of 3 and 4 were considered “borderline NASH” (Group 1b).

Table(1): Comparison between the studied groups as regard laboratory parameters.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group1</th>
<th>Group2</th>
<th>Group3</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1vs.2</td>
<td>1vs.3</td>
<td>2vs.3</td>
<td></td>
</tr>
<tr>
<td>FBG (mg/dl)</td>
<td>158±24</td>
<td>157±20</td>
<td>89±14</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>2h pp (mg/dl)</td>
<td>255±58</td>
<td>250±680</td>
<td>127±9</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Insulin(μiu/ml)</td>
<td>19.3 ±17</td>
<td>13.1± 6</td>
<td>12.1 ±4.1</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>HOMA</td>
<td>135.2±123</td>
<td>104± 38</td>
<td>49.4±20.5</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Resistin (ng/ml)</td>
<td>16.2± 4</td>
<td>6.8± 4.1</td>
<td>3.4±1.1</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

NAFLD patients were diagnostically categorized according to the histologically assessed NAFLD Activity Score into:

Group 1a: Ten cases were classified as “Not NASH” (Figure 1); they were 4 males and 6 females with mean age 46±8.6.

Group 1b: Twelve cases were classified as “Borderline NASH”; they were 8 males and 4 females with mean age 51.3±9.6.

Group 1c: Eighteen cases were classified as “NASH”; they were 8 males and 10 females with mean age 32.7±11.4.
Group 1c “NASH” had higher BMI, Hs CRP as well as resistin compared to group1a “Not NASH” and group 1b "Borderline NASH" (p < 0.01) as shown in table 2.

Table (2): Comparison between categories of NAFLD patients according to the histologic NAFLD activity score (NAS) as regard BMI and laboratory parameters.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group 1a (n= 10)</th>
<th>Group 1b (n= 12)</th>
<th>Group 1c ( n=18)</th>
<th>ANNOVA</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI (kg/m²)</td>
<td>21.8 ± 1.7</td>
<td>27.3 ± 2.5</td>
<td>33.6 ± 1.3</td>
<td>64.4</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>ALT</td>
<td>95 ± 11</td>
<td>96.3 ± 17.2</td>
<td>101.5 ± 1 5.5</td>
<td>0.38</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>AST</td>
<td>71.1±12.5</td>
<td>76 ±7.8</td>
<td>82.2±15.4</td>
<td>1.3</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>FBG</td>
<td>150±20</td>
<td>153±27</td>
<td>173±19</td>
<td>1.06</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>2hpp</td>
<td>156.6±60</td>
<td>190±90</td>
<td>273±65</td>
<td>2.7</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Resistin (ng/ml)</td>
<td>13.5±2.7</td>
<td>14±2.2</td>
<td>19.2±3.6</td>
<td>7.8</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Hs CRP (mg/dl)</td>
<td>2.3±2.2</td>
<td>3.9 ±1.5</td>
<td>5.9±1.7</td>
<td>6.5</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

Resistin had positive correlation to blood glucose, insulin, HOMA, liver enzymes, LDL cholesterol, TG and Hs CRP as shown in table 3.

Table3: Correlation of serum resistin to BMI and laboratory parameters.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>r</th>
<th>P-value</th>
<th>Parameter</th>
<th>r</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI</td>
<td>0.68</td>
<td>&lt;0.05</td>
<td>Total cholesterol</td>
<td>0.75</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>FBG</td>
<td>0.66</td>
<td>&lt;0.05</td>
<td>LDL</td>
<td>0.77</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>2hpp</td>
<td>0.68</td>
<td>&lt;0.05</td>
<td>TG</td>
<td>0.66</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Insulin</td>
<td>0.67</td>
<td>&lt;0.05</td>
<td>AST</td>
<td>0.91</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>HOMA</td>
<td>0.75</td>
<td>&lt;0.05</td>
<td>ALT</td>
<td>0.91</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Hs CRP</td>
<td>0.73</td>
<td>&lt;0.01</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Discussion:
This study essentially showed that NAFLD patients had higher serum resistin compared to obese and controls (16.2± 4 vs. 6.8± 4.1 and 3.4 ±1.1 respectively; p <0.01) and this increase was positively correlated with BMI, blood glucose and insulin resistance. The strong association between insulin resistance and NAFLD has been extensively demonstrated 9. Available evidence suggests that insulin resistance affects hepatic fat accumulation by increasing release of free fatty acids from adipose tissue, increasing fatty acid and triglycerides synthesis in the liver, reducing fatty acid oxidation and reducing very low-density lipoprotein (VLDL) production. Binding of adiponectin to its receptors stimulates phosphorylation of PPAR activity and fatty acid oxidation in liver and reducing fatty acid synthesis through inhibition of acyl-CoA carboxylase (ACC) and fatty acid synthase (FAS) expression and activity10, and this mechanism is inhibited by resistin, therefore increased resistin in NAFLD could result in increased fatty acid synthesis, accumulation...
of triglycerides, and reduced fatty acid oxidation via insulin resistance and inhibiting adiponectin action. Al-Harithy and Al-Ghamdi 17 found that serum resistin concentrations increased from lean (11.59 +/- 2.08) to OW/OB non-diabetic (16.29 +/- 2.29) to diabetic (19.42 +/- 3.60 ng/mL) (p<0.001). Furthermore, resistin showed significant positive correlation with insulin and HOMA in diabetic and non-diabetic subjects. Baranova et al 12 stated that serum resistin was higher in patients with insulin resistance than patients without insulin resistance and obese patients with insulin resistance have decreased serum adiponectin and increased serum resistin. Ciba and Widhalm 13 found an association between insulin resistance and NAFLD in obese children indicating that markers of insulin sensitivity could be useful screening parameters for NAFLD.

This study showed that advanced NAFLD was strongly associated with higher serum resistin, as Group 1c ' NASH' had higher resistin compared to group1a'Not NASH' and group 1b'Borderline NASH' (p< 0.01). The previous studies of the relationship between resistin and NAFLD were conflicting. Aller et al 14 confirmed that blood levels of resistin were higher in patients with a high grade of steatosis. On the other hand Cho et al 15 found that serum resistin levels were similar in Group I (normal liver), Group II (mild fatty liver)and Group III (moderate to severe fatty liver), while leptin levels increased with increasing degree of hepatic fat infiltration. Moreover Lee et al 16 found that there were no significant differences in serum leptin and resistin levels between two normal and increased ALT groups, while serum adiponectin levels were lower in the increased ALT group than in the normal ALT group. Furthermore Tsocchatzis et al 17 stated that there was no significant association between steatosis or necroinflammation and levels of adipokines, while the presence of moderate/severe fibrosis (stages 4-6) was associated with lower resistin.

We found a positive correlation between serum resistin and AST, ALT, Hs CRP (P<0.01). It is well known that inflammation is a key mechanism in the progression of fatty liver to hepatitis and cirrhosis. 17 Adipokines are believed to act through their effects on insulin sensitivity. Insulin resistance and hyperinsulinemia are also associated with the inflammatory and fibrotic reaction that complicates advanced stages of the disease 18, but new evidences indicate an important action on stimulation/inhibition of the inflammatory process. 19 Mojiminiyi and Abdella 20 stated that resistin may represent a link between obesity and insulin resistance via pro-inflammatory pathways. In NAFLD a self-perpetuating pathway between insulin resistance and inflammation may explain the necro-inflammatory

observed in the subset of patients with NASH. 21 in contradiction to our results Pagano et al 22 found no correlation between resistin and high-sensitivity C-reactive protein but they noted positive correlation between resistin and histological inflammatory score. Roberto et al 23 confirmed the significant direct association between Hs-CRP and resistin which might explain the inflammatory pathogenic role of resistin in aggravating liver histology as assessed by the NAFLD activity score.

Conclusion and recommendation:

Resistin has a role in pathogenesis of NAFLD, resistin level is a predictive of histology in NAFLD, so it can be used as a simple diagnostic biomarker for NAFLD.

Authors:
Amal Shawky Mohamed: Assistant professor of internal medicine, Ain Shams University, Cairo, Egypt.
Telephone: (+2) 011-176-9135.
E mail: amalshawky@hotmai.com

Engy Yousry Elsayed: lecturer of Internal Medicine, Ain Shams University, Cairo, Egypt.
Telephone: (+2) 010-690-5243
E mail: ashorengy@yahoo.com

Hala Abd Elal : lecturer of Clinical Pathology, Ain Shams University, Cairo, Egypt.
Telephone: (+2) 010-182-9096
E mail: hala_abdelal@yahoo.com

Iman H. Hewedi: lecturer of Pathology, Ain Shams University, Cairo, Egypt.
Telephone: (+2) 012-395-3221
E mail: imihewedi99@yahoo.com

References:


